Close

Novo Nordisk awarded contract by VA as primary source provider of insulin

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

InterSystems and MyCLNQ Health Partner to Advance Patient Engagement Across Asia

Partnership helps hospitals to extend reach beyond existing facilities...

Medical Supplierz Links Healthcare Buyers and Manufacturers

Medical Supplierz, which happens to be a digital B2B procurement platform,...

AI-Led Warning System Prompts To Trigger CQC Inspection

The CQC is going to carry out rapid response...

Medtech Startup Raises $35M in Pulsed Field Ablation

Field Medical by Steven Mickelsen has gone on to...

Novo Nordisk, a global healthcare company and leader in diabetes care, announced it has been awarded a contract by the U.S. Department of Veterans Affairs (VA) as the primary source provider of insulin. The one year contract began on March 1, 2010 and the VA has the option to renew the contract annually for up to an additional four years.

"We are very proud to continue our work with the Department of Veterans Affairs to supply innovative insulins to the VA patients who rely on our products," said Andy Ajello, vice president of National Diabetes Sales, Novo Nordisk Inc. "Novo Nordisk has supported the Veterans Administration for the past 10 years as the primary supplier of insulin and we look forward to working together to serve VA physicians and patients."

The contract provides Novo Nordisk with the opportunity to supply human insulin, NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]), and NovoLog® (insulin aspart [rDNA origin] injection) to the VA, which has an overall patient enrollment of more than eight million. Under this agreement, The Department of Defense, Indian Health Services and The Bureau of Prisons will also have access to the national contract pricing.

Latest stories

Related stories

InterSystems and MyCLNQ Health Partner to Advance Patient Engagement Across Asia

Partnership helps hospitals to extend reach beyond existing facilities...

Medical Supplierz Links Healthcare Buyers and Manufacturers

Medical Supplierz, which happens to be a digital B2B procurement platform,...

AI-Led Warning System Prompts To Trigger CQC Inspection

The CQC is going to carry out rapid response...

Medtech Startup Raises $35M in Pulsed Field Ablation

Field Medical by Steven Mickelsen has gone on to...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back